OncoMatch/Clinical Trials/NCT06153251
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Is NCT06153251 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including BMS-986453 and Fludarabine for relapsed and/or refractory multiple myeloma.
Treatment: BMS-986453 · Fludarabine · Cyclophosphamide — The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulatory agent
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- City of Hope Comprehensive Cancer Center · Duarte, California
- UCSF Helen Diller Medical Center at Parnassus Heights · San Francisco, California
- Stanford University Medical Center · Stanford, California
- Colorado Blood Cancer Institute · Denver, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify